Familial amyotrophic lateral sclerosis (ALS) accounts for 10% of all ALS cases; approximately 25% of these cases are due to mutations in the Cu/Zn superoxide dismutase gene (SOD1). To date, 105 different mutations spanning all 5 exons have been identified in the SOD1 gene. Mutant SOD1-associated ALS is caused by a toxic gain of function of the mutated protein. Therefore, regardless of the specific mechanism whereby mutant SOD1 initiates motor neuron death, the authors hypothesize that measures that decrease levels of mutant SOD1 protein should ameliorate the phenotype in transgenic mice and potentially in patients with SOD1-mediated disease. They have designed 2 cell-based screening assays to identify small, brain-permeant molecules that inactivate expression of the SOD1 gene or increase the degradation of the SOD1 protein. Here they describe the development and optimization of these assays and the results of high-throughput screening using a variety of compound libraries, including a total of more than 116,000 compounds. The majority of the hit compounds identified that down-regulated SOD1 were shown to be toxic in a cell-based viability assay or were nonselective transcription inhibitors, but work is continuing on a number of nonspecific inhibitors of SOD1 expression. Ultimately, the authors believe that these 2 cell-based assays will provide powerful strategies to identify novel therapies for the treatment of inherited SOD1-associated forms of ALS. (Journal of Biomolecular Screening 2006:729-735) 
INTRODUCTION
A MYOTROPHIC LATERAL SCLEROSIS (ALS) is a neurodegenerative condition characterized by death of large motor neurons in the brain and spinal cord in association with progressive clinical weakness, atrophy, and spasticity. ALS leads to paralysis and respiratory failure within 5 years of onset. ALS has a worldwide incidence of approximately 6 cases per 100,000 individuals, with no significant variations between different geographical locations. Familial ALS accounts for 10% of all ALS cases; approximately 25% of these cases are due to mutations in the Cu/Zn superoxide dismutase gene (SOD1). 1 To date, 105 different mutations, spanning all 5 exons, have been identified in the SOD1 gene. 2 Although rare mutations in the genes for dynactin 1, 3 ALS2, 4 senataxin, 5 and VAPB 6 cause motor neuron disease, SOD1 is the major ALS susceptibility gene.
Several lines of evidence argue that the mutant SOD1 protein is neurotoxic through an acquired, adverse function, although this remains to be defined. Transgenic expression of high levels of mutant SOD1 protein in mice produces a motor neuron disease phenotype, with age of onset and disease duration dependent on copy number. 7 The majority of mutant SOD1 proteins retain catalytic activity greater than 50% of the wild-type protein, suggesting that loss of dismutase function is not an invariable element in toxicity of mutant SOD1 protein. 8 Indeed, transgenic mice with 3 different SOD1 mutations were found to have increased or unchanged SOD1 activity in the brain and spinal cord. 7, 9 Transgenic mice expressing SOD1 G93A at approximately 5 times the level of endogenous mouse SOD1 develop a motor neuron disease phenotype, whereas the SOD1 G93A mice with a lower copy number do not. Analogously, in SOD1 G93A rats, only strains that express the highest level of mutant SOD1 protein develop ALS. 10 In addition, SOD1 knockout animals do not develop an overt motor neuron disease phenotype. 11 These studies strongly argue that the dose of the mutant protein is a critical determinant of the susceptibility of these animals to ALS, the timing of disease onset, and the rate of disease progression.
For this reason, measures that reduce the levels of the mutant, toxic proteins are expected to ameliorate the phenotype of mutant SOD1-mediated ALS. This view is strongly supported by recent studies showing that survival in ALS mice is substantially prolonged by application of RNAi to reduce spinal cord SOD1 levels. 12 There is also an outstanding precedent for reversal of a neurodegenerative disorder in transgenic HD mice following inactivation of a mutant allele. 13 Here we describe the development of 2 high-throughput screening (HTS) assays to identify compounds that reduce SOD1 expression or increase SOD1 protein degradation/clearance.
MATERIALS AND METHODS

Generation of SOD1 promoter-EGFP(Pr SOD1 -EGFP) reporter cell line
A total of 2.2 Kb of the SOD1 promoter region was amplified from human genomic DNA by PCR using Pfu Taq polymerase (New England Biolabs, Ipswich, MA). PCR primers used to amplify the region were as follows: forward primer 5´-AGAAT-CACTTGAACCCAGCA-3´ and reverse primer 5´-CGCCATA-ACTCGCTAGGCCACGC-3´. The 2.2-Kb fragment was first cloned into pGEM-T (Promega, Madison, WI) and then subcloned into the pEGFP-1 plasmid (Clontech, Mountain View, CA) using SalI and SacII restriction enzyme sites ( Fig. 1) . Rat pheochromocytoma PC12 cells were stably transfected with the SOD1 promoter construct using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Clonal cell lines were selected based on high levels of enhanced green fluorescent protein (EGFP) expression and cultured in DMEM-F12 (Gibco, Carlsbad, CA) containing 10% (v/v) horse serum, 5% (v/v) fetal bovine serum (FBS), 1 × penicillin, 1 × streptomycin, and 500 µg/mL G418 (Invitrogen).
Generation of SOD1 protein-EGFP (SOD1-EGFP) reporter cell lines
The 2-plasmid system based on the ecdysone-inducible mammalian expression system was used to direct SOD1-EGFP protein expression (Invitrogen). A heterodimeric Drosophila ecdysone receptor encoded by a first plasmid, in the presence of an inducer, regulates expression of the gene of interest from a second reporter plasmid. The reporter plasmid contains an ecdysone-responsive promoter upstream of the SOD1 cDNA sequence attached by a short linker to the EGFP gene. Plasmids have been constructed containing the human wild type and 3 different mutant SOD1 cDNA sequences (A4V, G37R, and G93A) inserted using KpnI and XbaI restriction enzyme sites ( Fig. 2) . Rat PC12 cells stably expressing the pVgRXR plasmid encoding the ecdysone receptor were transfected with the SOD1 protein-EGFP reporter plasmids using Lipofectamine 2000. Clonal cell lines were selected based on high levels of EGFP expression after induction with 5 µM muristerone (Invitrogen; see Fig. 3 ) and cultured in DMEM-F12 containing 10% (v/v) horse serum, 5% (v/v) FBS, 1× penicillin, 1× streptomycin, 500 µg/mL G418, and 100 µg/mL zeocin (Invitrogen).
High-throughput screening
The Pr SOD1 -EGFP and SOD1-EGFP cell lines were optimized for HTS in 96-well black-well/clear-bottom plates (cat. #1450-573, PerkinElmer, Wellesley, MA). The signal was not strong enough to further miniaturize to a 384-well plate format. For each cell line assay, performance in a 96-well format was determined by calculating the signal window and Z factor (Z´). 14 The Z´ value for a given assay is provided by the following equation:
where µ c+ and µ c-are the mean values of signal of the positive and negative controls in the assay, and σ c+ and σ c-are the standard deviations of the positive and negative controls. In each case, the positive control value is from untreated cells and the negative control from untransfected cells. Because the Z´ value describes the size of the signal window (µ c+ -µ c-) and the precision of the assay data (3σ c+ + 3σ C-), it is a critical indicator of the quality of an assay. For the SOD1-EGFP cell lines, muristerone (5 µM) was added to the media prior to plating the cells. For HTS, compounds were preplated robotically in triplicate at 5 µM in a 96-well plate and 100 µL of media added per well. The 
, extreme right column was empty, leaving the wells available for controls. The stably transfected cells were then dispensed over the compounds at 50,000 cells/well using an automated cell plater ( Compounds that reduced EGFP fluorescence by between 35% and 70% compared to untreated cells were designated as hits from the initial primary assays.
Compound libraries
Four libraries of compounds were available in the HTS laboratory at MGH: 3000 compounds from the Chembridge Corp. Libraries were delivered dissolved in DMSO or as a lyophilized powder in 96-well tube racks. Lyophilized powders were reconstituted in DMSO to 5 mg/mL. All compounds were stored desiccated at -20°C. The Pr SOD1 -EGFP cell line was screened against these libraries.
Cytotoxicity and dose-response testing
Cytotoxicity and dose-response analysis was carried out with the Pr SOD1 -EGFP and SOD1 G37R -EGFP cell lines used for the primary assays. Dose-response analyses confirmed that the candidate hit compounds inactivated SOD1 expression or increased SOD1 protein degradation/clearance in a dosedependent manner and allowed calculation of EC 50 values. In parallel, toxicity assays identified compounds producing a nonspecific decrease in EGFP fluorescence due to cellular toxicity.
Using the same format as the primary assays, the relevant cell line was plated in a 96-well plate with a range of compound concentrations (0-10 µM) and incubated for 72 h. Toxicity analysis was carried out first using the tetrazolium salt WST-1 (Roche, Penzberg, Germany). In this assay, cleavage of WST-1 to formazan by mitochondrial dehydrogenases causes a color change (red to yellow). WST-1 (20 µL per well) was added after compound treatment and incubated for 1 h at 37 °C. The absorbance was read at 420 nm and values compared to untreated cells. Subsequently, the cells were washed 3 times with 150 µL of 1× PBS using an automatic plate washer and lysed with 150 µL of RIPA buffer. The level of EGFP fluorescence was then read on a Victor 2 V fluorescent plate reader (PerkinElmer; excitation 485 nm, emission 535 nm). Compounds that failed to show greater than 25% inhibition at the 10-µM compound concentration in a dose-response curve or showed significant cellular toxicity (≥ 25% cell death at the 10-µM compound concentration) were excluded from further analysis.
Secondary assay
Western blot and enzyme-linked immunosorbent assays (ELISAs) were used to determine whether effects seen in the reporter cell lines could be reproduced on endogenous SOD1 protein levels. Rat PC12, human neuroblastoma (SHSY5Y), and human cervical carcinoma (HeLa) cell lines were plated at 60% confluence in a 6-well plate with hit compounds (0-20 µM). After 72 h, each well was washed once with 0.5 mL of 1 × PBS, then lysed and scraped with 100 µL of 1% Triton-X containing protease inhibitors (Roche). Protein concentrations were determined using a Bradford assay according to the manufacturer's instructions (Biorad, Hercules, CA).
Western blotting was then carried out using standard protocols and membranes probed first with an anti-SOD1 antibody (cat. #574597, Calbiochem, San Diego, CA) and then reprobed with an anti-β-actin antibody (cat. #A2066, Sigma, St. Louis, MO) as an internal control. ELISA assays were used to quantify differences in SOD1 protein levels using methods previously described. 15 
RESULTS
HTS using the Pr SOD1 -EGFP cell line
A stable cell line expressing EGFP under the control of a 2.2-Kb fragment of the SOD1 promoter has been generated and optimized for screening compounds that reduce SOD1 promoter activity as detected by a decrease in EGFP fluorescence in a 96-well format. The ratio of positive/negative signal (i.e., the ratio of the EGFP fluorescence from EGFP-expressing cells relative to the background fluorescence) was 3.48 for the Pr SOD1 -EGFP cell line.
The utility of this assay for HTS was assessed using 3 small compound libraries (Prestwick, TimTec, Chembridge), which were screened in triplicate in a 96-well format. The assay showed excellent reproducibility with an average Z´ value of 0.72 (range, 0.67-0.78). The effect of each compound was expressed as the degree of inhibition of EGFP fluorescence compared to untreated cells, and the well-to-well variation in this signal around 0% inhibition was kept within a narrow window, allowing the clear detection of compounds producing a significant level of inhibition (coefficient of variation [%CV] = 4.73; Fig. 4) . For the preliminary screening, low stringency parameters were chosen to identify hit compounds, allowing optimization of hit selection prior to screening of larger libraries.
During these initial screens, a total of 75 hit compounds were identified that inhibited SOD1 promoter activity by greater than 35% ( Table 1) . Twenty-five of these compounds produced more than 75% inhibition of SOD1 promoter activity. Toxicity assays indicated that this was a consequence of a nonspecific reduction in cell viability. Of the remaining 50 compounds, 43 were found to be false positives (i.e., the > 50% inhibition of SOD1 promoter activity at 5 µM, as seen in the primary assay, could not be reproduced in dose-response assays). Seven compounds were confirmed by dose-response assays to down-regulate SOD1 expression. When analyzed by Western blotting, these 7 compounds were again able to reduce the level of endogenous SOD1 protein, although a concomitant decrease in actin levels was observed. These compounds are therefore likely to be general transcriptional repressors. Although off-target effects are to be expected from any potential therapy, the observation of a down-regulation of actin levels suggests widespread effects on global expression. Toxicity was not observed with any of these 7 nonspecific hits within the concentration range tested. There are similarities in the structures of at least 2 of these nonspecific SOD1 repressors that suggest commonalities in their mechanisms of action ( Fig. 5) .
Following optimization in these small library screens, we screened 2 additional compound libraries with the Pr SOD1 -EGFP assay: a library of Food and Drug Administration (FDA)approved compounds (MicroSource) at MGH and a large multisource library of 110,000 compounds at the LDDN, Cambridge, MA. From these screens, we selected hit compounds that produced greater than 50% inhibition of EGFP levels compared to untreated cells. From the MicroSource library, 44 hit compounds were identified. Although the majority of these compounds also reduced overall cell viability, analysis is continuing on 2 compounds that reduced EGFP levels without compromising viability. Screening of the 110,000-compound LDDN collection identified 251 hit compounds, which reduced EGFP fluorescence by greater than 50%. Approximately half of the compounds showed a nonspecific effect on cell viability, and the remainder were mostly false positives, showing no dose dependency or activity at the screening concentration. However, 20 compounds showed a dose response and an absence of toxicity over a 0-to 20-µM range, although a decrease in actin levels was observed by Western blot analysis. Work is continuing on a number of these compounds that show nonspecific effects on SOD1 expression alongside those described above.
HTS using the SOD1 G37R -EGFP cell line
We generated stable PC12 cell lines expressing inducible fusion proteins consisting of either wild-type or mutant (A4V, G37R, G93A) SOD1 proteins linked to EGFP. The utility of this assay for HTS was assessed in a 96-well format using the SOD1 G37R -EGFP cell line to screen the Prestwick library of 640 compounds. The ratio of positive/negative signal (i.e., the ratio of the EGFP fluorescence from EGFP-expressing cells relative to the background fluorescence) was 3.48 for the Pr SOD1 -EGFP cell line. The assay showed excellent reproducibility with an average Z´ of 0.71 (range, 0.57-0.80). As described above for the Pr SOD1 -EGFP cell line, the degree of inhibition of EGFP fluorescence was compared to untreated cells. The well-to-well variation in this signal was within a narrow window (%CV = 6.57), allowing the clear detection of compounds producing a significant level of inhibition, as described above. Thirty hit compounds were identified that reduced SOD1 G37R -EGFP protein levels by greater than 35% ( Table 1) . Twenty of these 30 that had been toxic in the SOD1 reporter cell line (above) were again toxic in this SOD1 G37R -EGFP expression assay. The remaining 10 hit compounds were false positives, as their effects seen in the primary assay could not be reproduced in dose-response assays.
The MicroSource library of compounds was also screened using the SOD1 G37R -EGFP cell line, and 37 hit compounds were identified that reduced EGFP fluorescence by at least 50%. Although the majority of these compounds were found to be toxic, analysis is continuing on 2 compounds that show nonspecific effects on SOD1 expression to determine whether these compounds can be further optimized. 
DISCUSSION
The goal of this study was to develop cell-based assays to allow the identification of novel compounds that reduce the levels of SOD1 protein. We employed 2 different EGFP reporter systems to create assays able to detect compounds either decreasing SOD1 promoter activity or increasing SOD1 protein degradation.
The first assay aims to identify compounds that reduce SOD1 promoter activity and uses a 2.2-Kb fragment of the SOD1 promoter driving stable EGFP expression in PC12 cells. Screening of 116,680 compounds from 10 different compound libraries identified 370 hit compounds. Twenty-nine compounds were confirmed to reduce SOD1 promoter activity and did not demonstrate significant toxicity over the 72-h time course of our treatments. However, the most of these compounds reduced endogenous SOD1 and actin expression to a similar degree and thus are likely to be general transcriptional repressors. Achieving specificity when targeting gene expression is one of the potential problems with compounds identified through this assay. However, analysis is continuing with these compounds to determine whether they may be modified to produce greater efficacy and specificity.
A large number of false positives were identified from the Chembridge, Natural Product, Prestwick, and mixed library screens using the Pr SOD1 -EGFP assay. This may be due in part to the different thresholds used to select hits from these libraries. Hits from the first 3 libraries were chosen as compounds that reduced SOD1 promoter activity by greater than 35%. In contrast for the MicroSource library, compounds producing > 50% inhibition were chosen as hits, and the number of false-positive hits was much lower. In addition, the falsepositive rate decreased considerably during the later screening, when the signal window for the assay improved. It should also be noted that the majority of false positives were weakly active in the primary screens and dropped below the screening cutoff in dose-response analysis.
Our second HTS assay aims to identify compounds that reduce SOD1 protein levels and uses stably transfected inducible PC12 cells expressing wild-type, A4V, G37R, or G93A SOD1 protein linked to EGFP. The SOD1 G37R -EGFP cell line demonstrated the highest Z factor when tested in a 96-well format and was therefore used to screen the Prestwick and MicroSource compound libraries. Although no specific inhibitors of SOD1 protein levels were identified from these initial screens, we are now beginning screening of larger compound libraries with the SOD1-protein assay. The advantage of inducible cell lines as opposed to those continuously expressing mutant protein is that cells are not stressed by the presence of the mutant SOD1 protein until the time of the assay and therefore retain many properties of wild-type cells. In addition, having multiple cell lines expressing different mutant SOD1 proteins will allow us to examine the specificity of hit compounds to down-regulate mutant compared to wild-type SOD1 protein levels. This may potentially allow us to exploit some of the unique structural properties of the mutant SOD1 proteins. 16 Indeed a similar cell-based assay was able to identify compounds that reduce the levels of mutant Huntington protein in a Drosophila model of Huntington's disease. 17 We believe that the development of these novel assays provides an important tool in the search for new treatments not only for SOD1-mediated ALS but also for potentially sporadic ALS.
